268 related articles for article (PubMed ID: 18097777)
1. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.
Rivera F; Vega-Villegas ME; Lopez-Brea MF; Marquez R
Acta Oncol; 2008; 47(1):9-19. PubMed ID: 18097777
[TBL] [Abstract][Full Text] [Related]
2. Current situation of zalutumumab.
Rivera F; Salcedo M; Vega N; Blanco Y; López C
Expert Opin Biol Ther; 2009 May; 9(5):667-74. PubMed ID: 19379120
[TBL] [Abstract][Full Text] [Related]
3. [The current status of development of anti-EGFR antibodies].
Ura T
Gan To Kagaku Ryoho; 2010 May; 37(5):777-81. PubMed ID: 20495305
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab a novel drug in cancer treatment.
Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C
Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813
[TBL] [Abstract][Full Text] [Related]
6. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
[No Abstract] [Full Text] [Related]
7. Cetuximab, its clinical use and future perspectives.
Rivera F; Vega-Villegas ME; López-Brea MF
Anticancer Drugs; 2008 Feb; 19(2):99-113. PubMed ID: 18176106
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
9. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Chua YJ; Cunningham D
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
[TBL] [Abstract][Full Text] [Related]
10. Role of anti-EGFR target therapy in colorectal carcinoma.
Enrique AA; Gema PC; Jeronimo JC; Auxiliadora GE
Front Biosci (Elite Ed); 2012 Jan; 4(1):12-22. PubMed ID: 22201852
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.
Socinski MA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4597-601. PubMed ID: 17671148
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
[TBL] [Abstract][Full Text] [Related]
14. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Montagut C; Dalmases A; Bellosillo B; Crespo M; Pairet S; Iglesias M; Salido M; Gallen M; Marsters S; Tsai SP; Minoche A; Seshagiri S; Serrano S; Himmelbauer H; Bellmunt J; Rovira A; Settleman J; Bosch F; Albanell J
Nat Med; 2012 Jan; 18(2):221-3. PubMed ID: 22270724
[TBL] [Abstract][Full Text] [Related]
15. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
Watkins D; Cunningham D
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Xu W; Jing H; Zhang F
Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
[TBL] [Abstract][Full Text] [Related]
17. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: appraisal of a novel drug against colorectal cancer.
Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
[TBL] [Abstract][Full Text] [Related]
19. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Tamura K
Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
[TBL] [Abstract][Full Text] [Related]
20. Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.
Konieczkowski DJ; Garraway LA
Cell Res; 2013 Jan; 23(1):13-4. PubMed ID: 22847744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]